What question did this study set out to answer?

To evaluate the risk of new-onset arrhythmias and all-cause mortality associated with sodium-glucose cotransporter-2 (SGLT2) inhibitor use in patients with type 2 diabetes mellitus.

June 5, 2020SHILAP Revista de lepidopterologíaOpen Access

The association between SGLT2 inhibitors and new-onset arrhythmias: a nationwide population-based longitudinal cohort study

View Full Paper

Ask AI

Bookmark

Why the study?

Although clinical trials demonstrated cardiovascular benefits with SGLT2 inhibitors, no study had investigated their association with the risk of arrhythmias.

Does SGLT2 inhibitor use reduce the risk of new-onset arrhythmias and all-cause mortality in adults with type 2 diabetes mellitus?

Population

399,810 patients newly diagnosed with type 2 DM aged 20 years and older in Taiwan

Comparison

SGLT2 inhibitors vs non-SGLT2 inhibitors

Design

Nationwide population-based longitudinal cohort study

Authors

HCHung-Yi ChenChang Gung University JHJing‐Yang HuangChung Shan Medical University Hospital WSWun-Zhih SiaoChung Shan Medical University Hospital

Discussion

Member takes

Implication

Supports arrhythmia/mortality benefits in T2DM; hypothesis-generating and requires RCT confirmation before practice change.

Key Points

To evaluate the risk of new-onset arrhythmias and all-cause mortality associated with sodium-glucose cotransporter-2 (SGLT2) inhibitor use in patients with type 2 diabetes mellitus.
Retrospective population-based cohort study using Taiwan's National Health Insurance Research Database including 399,810 adults aged ≥20 years with newly diagnosed type 2 diabetes.
Performed 1:1 propensity score matching (79,150 SGLT2 inhibitor users vs. 79,150 non-users) based on age, sex, diabetes duration, and drug index date to analyze new-onset arrhythmias and all-cause mortality.
SGLT2 inhibitor use was associated with a significant reduction in new-onset arrhythmias compared to non-use (adjusted hazard ratio [aHR] 0.830; 95% CI 0.751–0.916; P = 0.0002).
SGLT2 inhibitor therapy was associated with a significant reduction in all-cause mortality (aHR 0.547; 95% CI 0.482–0.621; P = 0.0001).

Structured PICO

Does SGLT2 inhibitor use reduce the risk of new-onset arrhythmias and all-cause mortality in adults with type 2 diabetes mellitus?

Population

Adults aged 20 years and older newly diagnosed with type 2 diabetes mellitus (n=399,810 enrolled; 158,300 included in matched analysis) from Taiwan.

Intervention

SGLT2 inhibitors

Comparator

Non-SGLT2 inhibitors (1:1 propensity score-matched by sex, age, diabetes mellitus duration, and drug index date)

Outcome

All-cause mortality and new-onset arrhythmias (NOA)hard clinical

In a real-world nationwide cohort of patients with type 2 diabetes, SGLT2 inhibitor use was associated with significantly reduced risks of new-onset arrhythmias and all-cause mortality.

Cite This Study

Chen et al. (2020) studied this question.

synapsesocial.com/papers/69f6916ac2e2af49314405e2 https://doi.org/10.1186/s12933-020-01048-x

View Full Paper

Ask AI

Bookmark

The association between SGLT2 inhibitors and new-onset arrhythmias: a nationwide population-based longitudinal cohort study

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

The association between SGLT2 inhibitors and new-onset arrhythmias: a nationwide population-based longitudinal cohort study

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider